Zenflow has created the Innoflow device, a disruptive solution to treat urinary obstruction related to benign prostatic hyperplasia (BPH). This condition affects most men at some point in life and imposes a significant quality of life burden. Our device will provide durable symptom relief in a simple, office-based procedure using common flexible cystoscopy tools. This means that implantation is easier for the urologist and far less painful for the patient than with any other BPH device. We have a strong IP position, a 510(k) FDA pathway, established reimbursement precedents, and an extremely quick and capital-efficient path to market. We have achieved excellent cadaver results to demonstrate that the mechanism works. We’re now beginning animal studies and will get to first-in-man in late 2015.
We are targeting a $20 billion global market opportunity and can achieve 90% gross margins at scale. Our core team consists of Stanford Biodesign alumni with significant experience in medtech engineering, regulatory approval, and entrepreneurship, and our advisors include innovative Stanford urologists as well as extremely accomplished medtech entrepreneurs and executives.